The disclosure relates to a pharmaceutical composition comprising particular deferasirox (image shown) with an average particle size less than or equal to about 200 nm, a process for preparing such pharmaceutical composition, and its use in the treatment of chronic iron overload. The pharmaceutical composition may also include an excipient, a surface stabilizer, a viscosity building agent, a polymer and a surfactant. The nanosized deferasirox have a large surface area and solubility. The disclosure also relates to a method for treating chronic iron overload by administering said pharmaceutical composition.
